Community Health Media
  • Home
  • What We Do
  • Playlists
  • Content Library
    • HER2+
    • HR+
    • HER2-Low / Ultra-Low
    • Triple Negative
    • High Risk
  • Podcasts
    • Breast Friends
    • Apple Podcasts
    • Spotify
    • Amazon Music
    • iHeartRadio
    • Castbox
    • Goodpods
    • Pocket Casts
  • Contact Us
  • ···
        • Youtube
        • Facebook
        • LinkedIn
        • Instagram
    Community Health Media
    • Home
    • What We Do
    • Playlists
    • Content Library
      • HER2+
      • HR+
      • HER2-Low / Ultra-Low
      • Triple Negative
      • High Risk
    • Podcasts
      • Breast Friends
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • iHeartRadio
      • Castbox
      • Goodpods
      • Pocket Casts
    • Contact Us
    • ···
          • Youtube
          • Facebook
          • LinkedIn
          • Instagram
      Community Health Media
      • Home
      • What We Do
      • Playlists
      • Content Library
        • HER2+
        • HR+
        • HER2-Low / Ultra-Low
        • Triple Negative
        • High Risk
      • Podcasts
        • Breast Friends
        • Apple Podcasts
        • Spotify
        • Amazon Music
        • iHeartRadio
        • Castbox
        • Goodpods
        • Pocket Casts
      • Contact Us

      Expanding Germline Testing: Who Should Be Tested for PARP Eligibility?

      Germline testing guidelines have evolved — and now, more patients than ever qualify. Drs. Iyengar and Robson discuss the shift from selective testing to broader inclusion and why BRCA testing is critical in identifying candidates for adjuvant PARP inhibition.

      FacebookXRedditPinterestEmail

      You may also like

      Video

      Dr. Neil Iyengar & Dr. Mark Robson – PARP Inhibitors in Early Breast Cancer: Who and When to Treat

      1 min read
      Video

      Germline Testing in the Community: Practical Pathways Without Genetics Teams

      1 min read
      Video

      Adjuvant PARP Inhibition: Risk Stratification and Sequencing in High-Risk Patients

      1 min read
      Video

      Beyond BRCA: Emerging Germline Targets for PARP Inhibitors

      1 min read
      Video

      Hormone Receptor Status & BRCA: Does Subtype Matter for PARP Use?

      1 min read
      Video

      PARP vs. CDK4/6 Inhibitors: Which Comes First in HR+ BRCA+ Disease?

      1 min read

      Recommended Videos

      New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed

      4 months ago

      Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich

      4 months ago

      Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni

      4 months ago

      Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan

      4 months ago

      Community Health Ventures

      Address:

      2471 18th St NW
      Second Floor
      Washington, DC 20009

      Email: info@communityhealth.media

      Follow Us

      • youtube
      • facebook
      • linkedin
      • instagram

      Quick Links

      • About
      • KOL Playlists
      • Contact Us
      • Privacy Policy
      • Terms of Use

      Content By Topics

      • HER2+
      • HR+
      • Triple Negative
      • HER2-Low / Ultra-Low
      • High Risk

      Podcast Network

      • Breast Friends Podcast
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • Castbox
      • Goodpods
      • iHeartRadio
      • Pocket Casts
      © 2026 Community Health Technologies, Inc. All Rights Reserved